Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations.
Latest Ratings for BHVN
DateFirmActionFromTo Mar 2022MizuhoMaintainsBuy Jan 2022Morgan StanleyMaintainsEqual-Weight Nov 2021MizuhoMaintainsBuy